$107.95▾ 2.48%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.53cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
99th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+13.8%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 300% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Corcept Therapeutics Incorporated turns 153¢ of every reported profit-dollar into real cash. Revenue is growing at a steady pace. Its valuation sits in the richer end of its own recent range.
Key numbers
Valuation
EPS (TTM)$0.87
TTM (trailing 12 months, through fiscal Q3 FY2025)
Profitability
Net margin14.3%
TTM (trailing 12 months, through fiscal Q3 FY2025)
Size
Revenue (TTM)$741.17M
TTM (trailing 12 months, through fiscal Q3 FY2025)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Signals and key numbers are from the fiscal Q3 FY2025 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.